Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 16/20 | 0.87 |
| ▸ | WDR77 | Q9BQA1 | 6/20 | 0.87 |
| ▸ | METTL3 | Q86U44 | 9/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18571673 | 0.93 | PRMT5 (1.00) | PRMT5WDR77METTL3 | |
| SCHEMBL22509618 | 0.93 | PRMT5 (0.75) | PRMT5WDR77METTL3 | |
| SCHEMBL22509643 | 0.85 | PRMT5 (0.87) | PRMT5WDR77METTL3 | |
| SCHEMBL24595498 | 0.85 | PRMT5 (0.76) | PRMT5WDR77METTL3 | |
| SCHEMBL22002154 | 0.84 | PRMT5 (0.82) | PRMT5WDR77METTL3 | |
| SCHEMBL18571790 | 0.83 | PRMT5 (0.81) | PRMT5WDR77METTL3 | |
| SCHEMBL18571841 | 0.82 | PRMT5 (0.80) | PRMT5WDR77METTL3 | |
| SCHEMBL22002126 | 0.82 | PRMT5 (0.72) | PRMT5WDR77METTL3 | |
| SCHEMBL31123435 | 0.82 | PRMT5 (0.71) | PRMT5WDR77METTL3 | |
| SCHEMBL23313123 | 0.82 | METTL3 (1.00) | PRMT5WDR77METTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220112194-A1 | COMPOUNDS TARGETING PRMT5 | ALIGOS THERAPEUTICS, INC. | 2022-04-14 | — | — | US | disclosed |
| US-20220048922-A1 | COMPOUNDS TARGETING PRMT5 | ALIGOS THERAPEUTICS, INC. | 2022-02-17 | — | — | US | disclosed |
| US-11198699-B2 | Compounds targeting PRMT5 | ALIGOS THERAPEUTICS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200317686-A1 | COMPOUNDS TARGETING PRMT5 | ALIGOS THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| WO-2020205867-A1 | COMPOUNDS TARGETING PRMT5 | ALIGOS THERAPEUTICS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11198699-B2 | Compounds targeting PRMT5 | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 49/4885METTL3 289/4885 |
| US-20220112194-A1 | COMPOUNDS TARGETING PRMT5 | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 49/4885METTL3 289/4885 |
| US-20200317686-A1 | COMPOUNDS TARGETING PRMT5 | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 49/4885METTL3 289/4885 |
| US-20220048922-A1 | COMPOUNDS TARGETING PRMT5 | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 49/4885METTL3 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.